Product innovations in
oncology and intensive
care medicine
|
|
|
New approaches in science and
innovative product ideas were the
moving forces in the establishment
of biosyn in the year 1984. Today
the company is proud of its own
research center where the focus is
on the development of novel biotechnology
products.
biosyn’s primary marketing and product
development focus is in the
area of oncology, followed by intensive
care medicine and environmental
medicine. In oncology, biosyn
pursues not only in the development
of new products but also in the establishment
and implementation of the
Integrated Concept, which means
synergistic integration of standard
oncological therapies with complementary
methods, to enhance patient’s
quality of life.
Therapeutic oncology product pipeline:
New and non-toxic
The success of cancer therapeutics
is measured by achievement of
remissions, increase of recurrence
free or metastasis-free intervals and
the improvement of survival time
after primary therapy. To achieve
these therapeutic goals, a marked
therapy-induced toxicity and the
associated reduced quality of patient’s
life has to be accepted.
From the very beginning, biosyn’s
oncology product innovation had the
declared objective to develop nontoxic
therapies and therapeutic principles
that would achieve the desired
therapeutic goal without impairing
patient’s quality of life. The rapid
growth of scientific knowledge in the
field of tumor biology has progressed
the development of several new
„intelligent“ drugs. These drugs, by
influencing the body’s own immune
defense mechanism, have the ability
to indirectly interfere with the growth
of tumors or to positively affect the
metastatic behavior of the tumor
without major toxic side effects.
|